Endo Wins Dismissal Of FTC's Suit Over Impax Opioid Deal

By Khorri Atkinson · March 24, 2022, 3:40 PM EDT

Endo Pharmaceuticals on Thursday secured a D.C. federal court's dismissal of the Federal Trade Commission's antitrust suit accusing it of entering a second "pay-for-delay" agreement with Impax Laboratories to stave off...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

FEDERAL TRADE COMMISSION v. ENDO PHARMACEUTICALS INC. et al

Case Number

Court

District Of Columbia

Nature of Suit

Anti-Trust

Date Filed

January 25, 2021

Recent Articles By Khorri

July 28, 2022
Judge Mulls Feds', Tobacco Cos.' Decree On Health Warnings
July 01, 2022
Ky. Trial Judge Vacancy Tees Up Likely Biden-McConnell Deal
June 10, 2022
Fed. Circ. Eyes Eligibility Of Stanford's Transplant Testing IP
May 25, 2022
11th Circ. Nixes Suit By Atty Who Ended Mental Health Checks
May 23, 2022
Judge Skeptically Probes Fate Of FDA's Cigar Regulation
May 16, 2022
Providers Say 9th Circ. Ruling Helps BCBS Antitrust Case
April 11, 2022
DOJ Attys Escape Subpoena To Testify In Wage-Fixing Trial
March 22, 2022
3rd Circ. Upholds FTC Bid To Pause NJ Hospital Merger
March 18, 2022
DC Judge Ends 'Dormant' LabMD Suit Against FTC Attys
January 19, 2022
Biden Seeks To Expel Migrant Families; DC Circ. Is Skeptical